Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.

@article{Volk2000MethotrexateCI,
  title={Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.},
  author={Erin L. Volk and Kristin Rohde and Myungchull Rhee and John J. McGuire and Laurence A. Doyle and Douglas D. Ross and Erasmus Schneider},
  journal={Cancer research},
  year={2000},
  volume={60 13},
  pages={3514-21}
}
Cellular resistance to the antifolate methotrexate (MTX) is often caused by target amplification, uptake defects, or alterations in polyglutamylation. Here we have examined MTX cross-resistance in a human breast carcinoma cell line (MCF7/MX) selected in the presence of mitoxantrone, an anticancer agent associated with the multidrug resistance (MDR) phenotype. Examination of protein expression and enzyme activities showed that MCF7/MX cells displayed none of the classical mechanisms of MTX… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate.

Toxicology and applied pharmacology • 2016
View 8 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 58 references

MRP3, an organic anion transporter able to transport anti-cancer drugs.

Proceedings of the National Academy of Sciences of the United States of America • 1999

Similar Papers

Loading similar papers…